xCellSense®: Activity in Resistant Disease

Test Your Asset Where Standard of Care Has Already Failed

Benchmark single-agent and combination activity in primary cells from relapsed or refractory patients — the population where a new mechanism must demonstrate efficacy.

Request Scientific Consultation

Test in the hardest population

Resistance that develops in a patient is not reproduced by engineered or selected cell lines — it exists in that patient's cells. Much of it is also invisible to sequencing: relapse samples frequently show no newly actionable driver, because the resistance is adaptive rather than genomic.

xCellSense® benchmarks your asset in that patient's own live cells, against the agents they have already failed — measuring activity against resistance that actually developed, not a model of it.

A male scientist looking through a microscope

What we measure

Activity benchmarking
Single-agent and combination activity for your asset, measured against agents the patient has already failed.

Resistance mapping
Determine which agents demonstrate resistance and which retain activity across the tested drug panel within the same sample.

Retained sensitivity
Assess whether activity remains in cells unresponsive to the standard of care, and specify the relevant concentrations.

Genotype linkage (optional)
Combine this approach with NGS to determine whether the resistance is linked to a specific genomic driver or is an adaptive response.

Why it Matters

Resistant disease presents the most rigorous test and offers the strongest evidence for go/no-go decisions. It also supports the rationale for salvage combinations and provides a development case for partner evaluation.

Key Deliverables

Benchmarking against the agents that the patient has already failed, in the same cells

Cross-resistance profile across the reference panel and the investigational asset

Benchmarking vs. standard of care (SoC) in the same patient cells

Enrichment Criteria in Relapsed or Refractory Settings: Response Features Associated with Retained Sensitivity

Interpretation memo and underlying dataset, delivered in weeks, not months